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Controversy has recently arisen over the role of sirtuins in metazoan aging. In this issue of Cell
Reports, Banerjee et al. demonstrate that Drosophila Sir2 is necessary for life span extension in
response to dietary restriction and that its overexpression in the fat body increases the life span.The modern era of aging research was
ushered in with the demonstration that
aging could be regulated by manipulating
the levels of single proteins. Seminal
papers demonstrated insulin signaling’s
central role in aging in the worm
C. elegans and Sir2’s ability to increase
life span in the yeast S. cerevisiae (Kae-
berlein et al., 1999, and reviewed in Haigis
and Yankner, 2010). Soon after, Sir2’s
function in aging was confirmed in
C. elegans and in the fly D. melanogaster
(Rogina et al., 2002; Tissenbaum and
Guarente, 2001).
Further excitement about Sir2 and its
orthologs, the sirtuins, was fueled by the
demonstration that Sir2 is a NAD+-depen-
dent protein deacetylase (Imai et al.,
2000). This link with an intermediate
metabolite suggested that Sir2 enzymatic
activity could be coupled to metabolic
status, a model supported by the impor-
tant observation that S. cerevisiae Sir2 is
necessary for the life span extension that
occurs in response to calorie restriction
(reviewed in Haigis and Yankner, 2010).
These observations have been further
expanded in mammalian systems, and
individual sirtuin orthologs are emerging
as global metabolic regulators, controlling
the response to calorie restriction, pro-
tecting against age-associated diseases,
and extending the life span (Kanfi et al.,
2012).
However, a recent paper by Burnett
and colleagues cast doubt on the robust-
ness of the previously reported effects of
sirtuins on life span in C. elegans, indi-
cating that they may have failed to control
for genetic background and possible
mutagenic effects of transgene insertions
(Burnett et al., 2011). Indeed, the originalCell ReSir2 transgenic worm carried a mutation
in the Dyf2 gene (Burnett et al., 2011;
Viswanathan and Guarente, 2011), muta-
tions in which might extend the life span.
Outcrossing the strain to remove the
Dyf2mutation from the Sir2-overexpress-
ing strains either eliminated life span
extension (Burnett et al., 2011) or greatly
reduced it (Viswanathan and Guarente,
2011).
Burnett’s study also cast doubt on
a previous paper that reported Sir2-medi-
ated extension of the Drosophila life span
(Rogina et al., 2002). In that study, a GAL4
transgene was used to drive the overex-
pression of dSir2. Burnett’s experiments
showed that dSir2-overexpressing flies
lived no longer than flies carrying the
GAL4 transgene alone, indicating that
the original results may have been due
to improper controls (Burnett et al.,
2011). However, a second study, using
appropriate controls and an inducible
overexpression system to rule out strain
effects, showed a 50% life span exten-
sion when dSir2 was overexpressed (Ba-
uer et al., 2009).
Enter the new study by Banerjee et al. in
this issue of Cell Reports (Banerjee et al.,
2012). The authorsmake use of an elegant
genetic system that eliminates concerns
associated with previous studies. Driver
lines (tissue-specific or whole-organism)
expressing a modified GAL4 protein
whose transcriptional activity is depen-
dent on the drug RU486 are crossed to
UAS-reporter lines expressing either a
Sir2 RNAi construct (dSir2RNAi) or a dSir2
gene downstream of GAL4-DNA binding
sites. In the absence of RU486, the
modified Gal4 protein is expressed in
target tissues but remains transcription-ports 2, December 27, 2012 ª2012 Elsevier Incally silent; therefore, neither dSir2 nor
dSir2RNAi is expressed. However, in the
presence of RU486, the modified Gal4
becomes transcriptionally active, medi-
ating expression of dSir2 or dSir2RNAi in
only those tissues expressing the modi-
fied Gal4 protein. The use of the same
drivers for overexpression or knockdown
negates the effect of genetic background,
and the use of the same drug for knock-
down or overexpression of dSir2 further
eliminates concerns about possible
effects of the drug on life span.
Using this approach, Banerjee et al.
report a 22% increase in median life span
when flies are switched to a restricted diet
(dietary restriction [DR]; flies are fed
0.25% yeast in place of 2.5%–5% yeast).
This increase in life span in response to
DR is lost when dSir2 expression is sup-
pressed via RNAi. To determine where
dSir2 must be expressed to facilitate the
DR effect on life span, they use drivers
conferring specific expression in the fat
body or muscle. Remarkably, knockdown
of dSir2 expression in the fat body alone,
but not in muscle, suppresses the life
span effect of DR. No phenotype is
observed after dSir2 knockdown (in whole
flies, fat body, or muscle) when the flies
are grown on 5% yeast, demonstrating
the specific requirement for dSir2 in the
fat body under DR conditions.
Next, using the same muscle- and fat-
body-specific drivers and a UAS-dSir2
transgene, they show that overexpression
of dSir2 in the fat body alone, but not in
muscle, increases median life span by
32%. Moreover, in contrast to Burnett
(Burnett et al., 2011), they were able
to upregulate dSir2 expression to the
same extent as in control flies under1473. Open access under CC BY-NC-ND license.
DR conditions. They also report that over-
expression in the fat body of a constitu-
tively active FOXO protein, a critical
component of insulin signaling, increases
life span by 29% but not when dSir2 is
knocked down in the same tissue. This
observation supports the earlier studies
concluding that Sir2 mediates DR-depen-
dent life span extension and that overex-
pression of dSir2 mimics DR (reviewed in
Haigis and Yankner, 2010).
Why did different laboratories obtain
conflicting results? One likely reason is
the use of nonideal experimental systems,
even in the Burnett study. For example,
in that paper, the control strains lived
35%–50% longer than wild-type flies. It
also unclear what the Sir2 levels were in
these studies. This is a critical consider-
ation, because life span extension by
DR or by Sir2 overexpression shows
an inverted U-shaped (hormetic) dose
response. For example, an additional
copy of yeast SIR2 extends the life span,1474 Cell Reports 2, December 27, 2012 ª20whereas expression from a high-copy
plasmid is toxic (Kaeberlein et al., 1999).
This would be consistent with an indepen-
dent report that Sir2 extends the worm life
span when integrated as a low-copy
transgene (Rizki et al., 2011).
The paper by Banerjee et al. in this issue
of Cell Reports helps resolve the contro-
versy about sirtuins and aging, and it high-
lights the fact that the multifactorial
process of aging can be profoundly
affected by genetic background, expres-
sion levels of transgenes, tissue-specific
expression, and other variables linked to
distinct experimental systems.
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